Business Trends– category –
-
Cartesian Therapeutics and WestGene Biopharma Announce Strategic Licensing Agreement to Accelerate In Vivo CAR T Platform Development for Autoimmune Diseases
BioSpace (Cartesian Therapeutics) USA Overview Cartesian Therapeutics announced a strategic licensing agreement with WestGene Biopharma to accelerate the development of novel in vivo Chimeric Antigen Receptor T-cell (CAR-T) therapies for... -
ENCell Secures US Clinical Manufacturing Contract for Ingenium Therapeutics’ NK Cell Therapy Gengleucel, Expanding Global CDMO Operations
Bio South Korea Overview ENCell, a South Korean CDMO specializing in cell and gene therapy, has signed an additional CMO contract with Ingenium Therapeutics for the manufacturing of clinical trial materials for its NK cell therapy candid... -
Alcami Expands CDMO Packaging Capabilities with Tjoapack Acquisition, Strengthening Cell and Gene Therapy Supply Chain
North Carolina Biotechnology Center USA Overview Alcami Corporation, a Contract Development and Manufacturing Organization (CDMO), has significantly expanded its packaging capabilities through the acquisition of global contract packaging... -
Made Scientific and Pluristyx Form Strategic Partnership to Integrate iPSC Technology and Expand Cell Therapy Manufacturing CDMO Services
BioPharm International USA Overview Made Scientific announced a strategic partnership with Pluristyx, an iPSC technology platform provider, to integrate iPSC technology into its cell therapy CDMO services. This collaboration will provide... -
FUJIFILM Cellular Dynamics Opens New iPSC Manufacturing Facility and Reorganizes Life Sciences Leadership to Accelerate Cell Therapy and iPSC Business Expansion
FUJIFILM Cellular Dynamics / Indian Pharma Post Japan Overview FUJIFILM Cellular Dynamics announced the opening of its new headquarters and iPSC development and manufacturing facility in Madison, tripling its iPSC-based research product ... -
FDA Issues Draft Guidance to Streamline Regulatory Submissions for Cell and Gene Therapy Products by Leveraging Prior Knowledge
Pharmuni USA Overview The U.S. FDA has released new draft guidance aimed at accelerating the development of cell and gene therapy products for rare diseases. This guidance permits developers to leverage existing scientific, manufacturing... -
Stem Cell Therapies for Parkinson’s Disease Advance to Clinical Stages: BlueRock’s Phase 3 and Japanese iPSC Program Lead the Way
NeurologyLive USA Overview Stem cell therapies for Parkinson's Disease, particularly dopamine cell replacement trials, are making significant strides into advanced clinical stages. BlueRock Therapeutics' embryonic stem cell (ESC)-derived... -
Beam Therapeutics’ Gene-Editing Candidate BEAM-302 Shows Positive Clinical Data in AATD Treatment, Hinting at Accelerated FDA Pathway
Simply Wall St USA Overview Beam Therapeutics reported positive clinical trial data for its gene-editing candidate, BEAM-302, demonstrating sustained protective protein levels in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). Th... -
Century Therapeutics’ iPSC-Derived Type 1 Diabetes Therapy CNTY-813 Demonstrates Durable Glucose Control and Immune Evasion in Preclinical Studies
BioSpace (Century Therapeutics) USA Overview Century Therapeutics announced groundbreaking preclinical data for its iPSC-derived islet replacement therapy, CNTY-813, designed for Type 1 Diabetes (T1D) with Allo-Evasion™ 5.0 technology, a... -
Fate Therapeutics Presents Positive Clinical and Preclinical Data for iPSC-Derived Off-the-Shelf CAR T Therapies FT819, FT839, and FT836 in Autoimmune Diseases and Solid Tumors
Fate Therapeutics USA Overview Fate Therapeutics unveiled updated clinical and preclinical data for its iPSC-derived off-the-shelf CAR T-cell programs at EULAR and in corporate presentations. The Phase 1 trial for anti-CD19 CAR T-cell th...
